BlackRock
CLDX icon

BlackRock’s Celldex Therapeutics CLDX Stock Holding History

BlackRock’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$261M Buy
7,002,530
+1,632,645
+30% +$52.7M ﹤0.01% 1629
2026
Q1 		$170M Sell
5,369,885
-81,930
-2% -$2.23M ﹤0.01% 1767
2025
Q4 		$148M Sell
5,451,815
-54,173
-1% -$1.43M ﹤0.01% 1869
2025
Q3 		$142M Sell
5,505,988
-44,028
-0.8% -$1.02M ﹤0.01% 1872
2025
Q2 		$113M Buy
5,550,016
+25,884
+0.5% +$504K ﹤0.01% 1963
2025
Q1 		$100M Buy
5,524,132
+43,462
+0.8% +$971K ﹤0.01% 1986
2024
Q4 		$138M Buy
5,480,670
+600,650
+12% +$16.3M ﹤0.01% 1885
2024
Q3 		$166M Buy
4,880,020
+189,259
+4% +$7.21M ﹤0.01% 1771
2024
Q2 		$174M Buy
4,690,761
+178,837
+4% +$6.75M ﹤0.01% 1700
2024
Q1 		$189M Buy
4,511,924
+836,232
+23% +$34.3M ﹤0.01% 1676
2023
Q4 		$146M Buy
3,675,692
+423,738
+13% +$12.5M ﹤0.01% 1863
2023
Q3 		$89.5M Buy
3,251,954
+29,967
+0.9% +$939K ﹤0.01% 2057
2023
Q2 		$109M Sell
3,221,987
-28,651
-0.9% -$966K ﹤0.01% 1984
2023
Q1 		$117M Buy
3,250,638
+25,922
+0.8% +$1.12M ﹤0.01% 1911
2022
Q4 		$144M Buy
3,224,716
+94,303
+3% +$3.37M ﹤0.01% 1760
2022
Q3 		$88M Sell
3,130,413
-21,056
-0.7% -$646K ﹤0.01% 2049
2022
Q2 		$85M Buy
3,151,469
+104,647
+3% +$3.04M ﹤0.01% 2128
2022
Q1 		$104M Sell
3,046,822
-54,208
-2% -$1.73M ﹤0.01% 2120
2021
Q4 		$120M Sell
3,101,030
-32,740
-1% -$1.43M ﹤0.01% 2086
2021
Q3 		$169M Buy
3,133,770
+433,120
+16% +$20.3M ﹤0.01% 1845
2021
Q2 		$90.3M Buy
2,700,650
+1,732,777
+179% +$47.6M ﹤0.01% 2317
2021
Q1 		$19.9M Buy
967,873
+106,492
+12% +$2.45M ﹤0.01% 3184
2020
Q4 		$15.1M Buy
861,381
+69,785
+9% +$1.26M ﹤0.01% 3156
2020
Q3 		$11.7M Buy
791,596
+379,144
+92% +$4.44M ﹤0.01% 3135
2020
Q2 		$5.36M Buy
412,452
+67,969
+20% +$301K ﹤0.01% 3494
2020
Q1 		$572K Buy
344,483
+2,264
+0.7% +$5.12K ﹤0.01% 4027
2019
Q4 		$763K Sell
342,219
-273
-0.1% -$633 ﹤0.01% 4075
2019
Q3 		$729K Buy
342,492
+1,554
+0.5% +$3.6K ﹤0.01% 4079
2019
Q2 		$914K Buy
340,938
+37,820
+12% +$128K ﹤0.01% 4034
2019
Q1 		$1.49M Buy
303,118
+178,593
+143% +$939K ﹤0.01% 3798
2018
Q4 		$370K Sell
124,525
-128,919
-51% -$633K ﹤0.01% 4123
2018
Q3 		$1.72M Buy
253,444
+14,882
+6% +$104K ﹤0.01% 3826
2018
Q2 		$1.8M Sell
238,562
-434,603
-65% -$5.81M ﹤0.01% 3775
2018
Q1 		$23.5M Buy
673,165
+11,118
+2% +$431K ﹤0.01% 2675
2017
Q4 		$28.2M Buy
662,047
+18,619
+3% +$798K ﹤0.01% 2606
2017
Q3 		$27.6M Buy
643,428
+19,590
+3% +$734K ﹤0.01% 2620
2017
Q2 		$23.1M Buy
623,838
+82,484
+15% +$3.65M ﹤0.01% 2712
2017
Q1 		$29.3M Buy
541,354
+539,778
+34,250% +$28.1M ﹤0.01% 2522
2016
Q4 		$84K Buy
1,576
+64
+4% +$3.64K ﹤0.01% 2659
2016
Q3 		$91K Buy
1,512
+31
+2% +$1.93K ﹤0.01% 2652
2016
Q2 		$98K Buy
1,481
+1,045
+240% +$66.3K ﹤0.01% 2548
2016
Q1 		$25K Buy
436
+245
+128% +$27.6K ﹤0.01% 2736
2015
Q4 		$44K Buy
191
+31
+19% +$6.76K ﹤0.01% 2130
2015
Q3 		$26K Hold
160
– – ﹤0.01% 2225
2015
Q2 		$61K Sell
160
-7
-4% -$2.78K ﹤0.01% 1913
2015
Q1 		$70K Sell
167
-8
-5% -$2.86K ﹤0.01% 1845
2014
Q4 		$48K Hold
175
– – ﹤0.01% 1968
2014
Q3 		$34K Hold
175
– – ﹤0.01% 2093
2014
Q2 		$43K Buy
175
+27
+18% +$6.1K ﹤0.01% 2002
2014
Q1 		$39K Sell
148
-39
-21% -$14.9K ﹤0.01% 2026
2013
Q4 		$68K Buy
187
+5
+3% +$1.93K ﹤0.01% 1833
2013
Q3 		$97K Hold
182
– – ﹤0.01% 1670
2013
Q2 		$43K Buy
+182
New +$35.8K ﹤0.01% 1919

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

BlackRock's CLDX Position: Q2 2026 in Review

BlackRock increased its Celldex Therapeutics (CLDX) stake by 30% in Q2 2026, buying an estimated $52.7M and bringing the position to 7,002,530 shares worth $261M. The position accounts for ﹤0.01% of the portfolio, ranked #1629.

BlackRock first reported a position in CLDX in Q2 2013 and has held it in 53 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • BlackRock held 7,002,530 shares of Celldex Therapeutics worth $261M as of Q2 2026.
  • BlackRock bought 1,632,645 Celldex Therapeutics shares in Q2 2026, an estimated $52.7M.
  • Celldex Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1629 holding.
  • BlackRock first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.